enGene (NASDAQ:ENGN) Releases Earnings Results, Beats Estimates By $0.11 EPS

enGene (NASDAQ:ENGN) posted its quarterly earnings results on Monday. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.11, Zacks reports.

Here are the key takeaways from enGene’s conference call:

• Management attributes a combined effect of protocol amendments (T1 re‑resection, TA reinduction, routine biopsy) plus improved clinical execution for an estimated ≈21 percentage‑point improvement in the six‑month complete response rate.
• The program has received RMAT and CDRP designations and aligned the primary endpoint with the FDA to CR “at any time,” and management says ongoing SAP discussions increase confidence toward approval.
• Management states the safety database (the largest in the space at 125 patients) is sufficient and reports tolerability as near “best‑in‑class” with treatment discontinuations around 1–2%.
• They emphasize strong commercial fit in community urology: a non‑viral therapy with simple storage/handling, short clinic administration potentially by APP/staff, favorable buy‑and‑bill economics, and pricing flexibility to maximize market value.
• Company reports a cash runway into the second half of 2028, expects a potential approval in 2027, and plans interim 12‑month data updates (Q2 conference and H2), supporting a near‑term BLA path.

enGene Stock Down 2.1%

enGene stock traded down $0.15 during trading on Tuesday, hitting $6.90. 498,845 shares of the company were exchanged, compared to its average volume of 355,040. The business’s 50 day moving average is $9.54 and its 200 day moving average is $8.09. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. enGene has a 52 week low of $2.65 and a 52 week high of $12.25. The company has a market capitalization of $462.23 million, a P/E ratio of -3.06 and a beta of -0.29.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of enGene in a research report on Friday, January 9th. Citizens Jmp lifted their price objective on enGene from $18.00 to $21.00 and gave the stock a “market outperform” rating in a research report on Wednesday, November 12th. Citigroup reiterated a “market outperform” rating on shares of enGene in a research note on Monday, January 5th. UBS Group increased their price objective on enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a research report on Wednesday, November 12th. Finally, Jefferies Financial Group started coverage on shares of enGene in a report on Friday, January 30th. They issued a “buy” rating and a $28.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $23.29.

Institutional Trading of enGene

Institutional investors have recently added to or reduced their stakes in the company. Cresset Asset Management LLC acquired a new position in shares of enGene during the 2nd quarter worth approximately $36,000. Paloma Partners Management Co purchased a new stake in shares of enGene during the second quarter valued at $38,000. Raymond James Financial Inc. raised its holdings in shares of enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares in the last quarter. Jump Financial LLC bought a new stake in enGene in the fourth quarter worth $121,000. Finally, Millennium Management LLC boosted its stake in enGene by 57.3% during the third quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after buying an additional 7,472 shares during the period. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.